ArticleOncotarget2017
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Article
- Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in Chronic Respiratory Diseases: A Comprehensive Review.Cureus · 2025Review
- Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors.Scientific reports · 2024Article
- The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer.International journal of molecular sciences · 2024Article
- Effects of Reduced Extracellular Sodium Concentrations on Cisplatin Treatment in Human Tumor Cells: The Role of Autophagy.International journal of molecular sciences · 2024Article
- CARDS, a Novel Prognostic Index for Risk Stratification and In-Hospital Monitoring.Journal of clinical medicine · 2024Article
- Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors.Immunotherapy · 2024Article
- Hyponatremia Promotes Cancer Growth in a Murine Xenograft Model of Neuroblastoma.International journal of molecular sciences · 2023Article
- Long-term low-dose tolvaptan efficacy and safety in SIADH.Endocrine · 2023Article
- Hyponatremia and Cancer: From Bedside to Benchside.Cancers · 2023Review
- Hyponatremia and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2021Review
- Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.International urology and nephrology · 2021Article
- Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis.Translational lung cancer research · 2021Article
- Hypernatremia at admission predicts poor survival in patients with terminal cancer: a retrospective cohort study.BMC palliative care · 2020Article
- Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study.Oncology and therapy · 2020Article
- Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro.Endocrine · 2020Article
- Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management.Therapeutics and clinical risk management · 2020Review
- Hyponatremia and hypercalcemia: a study of a large cohort of patients with lung cancer.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to assess, for the first time, the prognostic role of hyponatremia and sodium normalization in patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer.Four hundred thirty-three patients with advanced non small cell lung cancer were treated with first line chemo- or targeted therapy between 2006 and 2015 at our institutions. Patients were stratified in two groups, with or without hyponatremia (group A and B, respectively). Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. A Cox regression model was carried out for univariate and multivariate analyses.Sixty-nine patients (16%) presented with hyponatremia at the start of first-line therapy. The median OS was 8.78 months in Group A and 15.5 months in Group B (p < 0.001), while the median PFS was 4.1 months and 6.3 months respectively (p = 0.24). In Group A, median OS was significantly higher in patients who normalized their sodium levels (11.6 vs. 4.7 months, p = 0.0435). Similarly, the median PFS was significantly higher in patients who normalized their sodium levels (6.7 vs. 3.3 months, p = 0.011). At multivariate analysis, sodium normalization was an independent prognostic factor for both OS and PFS.Sodium normalization during first-line therapy is an independent prognostic factor for OS and PFS in patients with advanced lung cancer treated with first-line therapies. Frequent clinical monitoring and prompt treatment of hyponatremia should be emphasized to optimize the outcome of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.